Monitor the sNDA submission for selinexor in myelofibrosis in August 2026 and any FDA feedback; a positive outcome could be a major catalyst. Also watch for announcements regarding financing or strategic alternatives, which could lead to dilution or a sale of the company.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 31 $1.92entry
- T+1 · 4mo ago +2.60%α +1.18% · $1.97
- T+5 · 3mo ago +10.42%α +6.91% · $2.12
- T+20 · 3mo ago −2.60%α −5.59% · $1.87
- T+60 · 22d ago −74.89%α −77.35% · $0.4821
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Karyopharm announced Phase 3 XPORT-EC-042 trial failure for selinexor in endometrial cancer (PFS p=0.0791, not significant), while simultaneously disclosing plans to submit an sNDA for selinexor in myelofibrosis in August 2026 under accelerated approval, though the FDA has requested further discussion on supporting data. The company is also exploring financing and strategic alternatives with Centerview Partners to extend its cash runway, signaling financial pressure.
Key Facts
- Phase 3 XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer failed to meet primary endpoint of PFS (HR=0.76, p=0.0791, not statistically significant)
- Company plans to submit sNDA for selinexor + ruxolitinib in myelofibrosis in August 2026 under accelerated approval pathway
- FDA provided written feedback that SVR35 qualifies as a surrogate endpoint but requires further discussion on data to support sNDA and conversion to traditional approval
- Company exploring financing transactions and strategic alternatives with Centerview Partners to extend cash runway; no assurance of any transaction
- Trial results do not affect ongoing trials of selinexor in other indications
Financial Impact
No financial figures provided in the filing; the failed trial removes a potential revenue stream, while the myelofibrosis sNDA represents a key pipeline catalyst. Cash runway concerns are highlighted by the strategic alternatives exploration.
Risk Factors
- FDA may not accept the sNDA or may require additional data, delaying or preventing accelerated approval
- Failed endometrial cancer trial reduces pipeline optionality and may impair investor confidence
- Company may need to raise capital on dilutive terms or fail to secure financing, increasing going-concern risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-326995 |
| Document: 0001193125-26-326995-index-headers.html | 0001193125-26-326995 |
| Document: 0001193125-26-326995-index.html | 0001193125-26-326995 |
| Document: 0001193125-26-326995.txt | 0001193125-26-326995 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers